Ono Pharma Submits an Application for Approval of Ripretinib (DCC-2618) in Patients with Advanced Gastrointestinal Stromal Tumor in Japan [Yahoo! Finance]
Ono Pharmaceutical (TSE:4528) Valuation Check As New Neurology And Rare Disease Partnerships Advance [Yahoo! Finance]
Sinopia Biosciences Announces Target Discovery Collaboration with Ono Pharmaceutical for Rare Metabolic Disorders [Yahoo! Finance]
Ono Pharma Announces New Drug Discovery Collaboration with Congruence Therapeutics in the Priority Areas of Neurology and Immunology [Yahoo! Finance]
Congruence and Ono Pharma Expand Multi-Target Research Partnership with the Addition of Two New Programs [Yahoo! Finance]